[Influence of lactobacterin on the upper respiratory tract microflora of subjects with microflora disorders].
High respiratory tract microflora recovery has been revealed in human subjects treated perorally with commercial Lactobacterinum. In most of the participants in the study, different (up to epidemically significant) values of disbiotic shifts including persistence of conventional pathogens (enterobacteria) and pathogenic staphylococci in high respiratory tract mucosa as well as nasopharyngeal lactoflora deficiency were observed in the pretreatment period. Significant, in the order of one to four, decreases in pathogenic microflora count up to complete elimination were accompanied by lactoflora restoration in a part of the subjects after treatment. Hence, Lactobacterinum seems to be a perspective means for correcting and optimizing the high respiratory tract microflora, especially in contingents subjected to the environmental factors with a high risk of disbiotic disorders.
Korniushenkova
I N
IN
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001430:Bacteriocins / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D006801:Humans; D009297:Nasal Mucosa / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000254:growth & development / Q000302:isolation & purification*
D000900:Anti-Bacterial Agents; D001430:Bacteriocins; C008244:lactobacterin
Vliianie laktobakterina na sostav mikrobiotsenozov verkhnikh dykhatel'nykh puteĭ u lits s narusheniiami mikroflory.